Press Releases

Printer Friendly Version View printer-friendly version
<< Back
Download PDF Download PDF
Vitae President and CEO Jeff Hatfield has been elected to the Board of Directors of the Biotechnolog Industry Organization

FORT WASHINGTON, Pa.— Vitae Pharmaceuticals today announced Jeffrey Hatfield, the Company’s President and Chief Executive Officer, was elected to the Board of Directors of the Biotechnology Industry Organization (BIO), effective immediately. During his 2011‐2012 tenure on the BIO Board, Mr. Hatfield will initially serve on two Governing Committees: the Intellectual Property committee and the Emerging Company Section Capital Formation committee.

Mr. Hatfield commented, “I am honored to join the Board of BIO. The organization is essential to the advancement of biotechnology, and I feel privileged to have the opportunity to collaborate with a well‐respected group of leaders on the industry’s advocacy, issues and policies.”

About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical‐stage biopharmaceutical company discovering and developing a portfolio of novel, small molecule, best‐in‐class compounds that address important disease areas, including: chronic kidney disease, diabetes, Alzheimer’s disease and atherosclerosis. Vitae’s lead compound, VTP‐27999, is a wholly owned, novel, potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. The compound is expected to enter Phase 2b in early 2012.

Vitae is expert in structure‐based drug discovery and combines a proprietary technical platform with the experience and insight of world class scientists to advance best‐in‐class compounds for high value, hard‐to‐drug targets. Vitae’s proprietary, discovery platform has clear advantages in creating and analyzing novel drug candidates that meet pre‐defined physicochemical and biochemical characteristics. The accuracy and speed of this system has enabled Vitae to solve challenging targets in multiple therapeutic areas – discovering and advancing attractive compounds in a rapid and highly capital efficient manner. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors; its last venture round was in 2004. Vitae’s 45 scientists are located in Fort Washington, Pennsylvania. For additional information, please visit the company’s website, www.vitaepharma.com.

About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry‐leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.”

Contacts
Burns McClellan on behalf of Vitae
Justin Jackson / Michelle Szwarcberg (media)
212‐213‐0006
jjackson@burnsmc.com
mszwarcberg@burnsmc.com

Source: Vitae Pharmaceuticals